ArticleFrontiers in medicine2021
An Open Label Trial to Assess Safety of Losartan for Treating Worsening Respiratory Illness in COVID-19.
Article in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- A Review of In Silico Research, SARS-CoV-2, and Neurodegeneration: Focus on Papain-Like Protease.Neurotoxicity research · 2022Pooled it
- Design, Conduct, and Analysis of Externally Controlled Trials.JAMA network open · 2025Article
- Article
- Discovery of Chalcone-Based Hybrid Structures as High Affinity and Site-Specific Inhibitors against SARS-CoV-2: A Comprehensive Structural Analysis Based on Various Host-Based and Viral Targets.International journal of molecular sciences · 2023Article
- An overview on the treatments and prevention against COVID-19.Virology journal · 2023Review
- Telmisartan Nanosuspension for Inhaled Therapy of COVID-19 Lung Disease and Other Respiratory Infections.Molecular pharmaceutics · 2023Article
- COVIDMED - An early pandemic randomized clinical trial of losartan treatment for hospitalized COVID-19 patients.Contemporary clinical trials communications · 2022Article
- Repurposing of Chemotherapeutics to Combat COVID-19.Current topics in medicinal chemistry · 2022Article
- Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management.Pneumonia (Nathan Qld.) · 2021Review
- A Multidisciplinary Approach to Coronavirus Disease (COVID-19).Molecules (Basel, Switzerland) · 2021Review
- The Molecular Basis of COVID-19 Pathogenesis, Conventional and Nanomedicine Therapy.International journal of molecular sciences · 2021Review
- Present and future treatment strategies for coronavirus disease 2019.Future journal of pharmaceutical sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.